adaptive covid-19 treatment trial 3 (actt-3)

Conditions: COVID-19

Summary: actt-3 will evaluate the combination of interferon beta-1a and remdesivir compared to remdesivir alone. subjects will be assessed daily while hospitalized. if the subjects are discharged from the hospital, they will have a study visit at days 15, 22, and 29. for discharged subjects, it is preferred that the day 15 and 29 visits are in person to obtain safety laboratory tests and oropharyngeal (op) swab and blood (serum only) samples for secondary research as well as clinical outcome data. however, infection control or other restrictions may limit the ability of the subject to return to the clinic. in this case, these visits may be conducted by phone, and only clinical data will be obtained. the day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. the primary outcome is time to recovery by day 29.

this study is an adaptive randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with covid-19. the study is a multicenter trial that will be conducted in up to approximately 100 sites globally. the study will compare different investigational therapeutic agents to a control arm. new arms can be introduced according to scientific and public health needs. there will be interim monitoring to allow early stopping for futility, efficacy, or safety. if one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). any such change would be accompanied by an updated sample size. this adaptive platform is used to rapidly evaluate different therapeutics in a population of those hospitalized with moderate to severe covid-19. the platform will provide a common framework sharing a similar population, design, endpoints, and safety oversight. new stages with new therapeutics can be introduced. one independent data and safety monitoring board (dsmb) will actively monitor interim data in all stages to make recommendations about early study closure or changes to study arms. actt-3 will evaluate the combination of interferon beta-1a and remdesivir compared to remdesivir alone. subjects will be assessed daily while hospitalized. if the subjects are discharged from the hospital, they will have a study visit at days 15, 22, and 29. for discharged subjects, it is preferred that the day 15 and 29 visits are in person to obtain safety laboratory tests and oropharyngeal (op) swab and blood (serum only) samples for secondary research as well as clinical outcome data. however, infection control or other restrictions may limit the ability of the subject to return to the clinic. in this case, these visits may be conducted by phone, and only clinical data will be obtained. the day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. all subjects will undergo a series of efficacy, safety, and laboratory assessments. safety laboratory tests and blood (serum and plasma) research samples and oropharyngeal (op) swabs will be obtained on days 1 (prior to infusion) and days 3, 5, 8, and 11 (while hospitalized). op swabs and blood (serum only) plus safety laboratory tests will be collected on day 15 and 29 (if the subject attends an in-person visit or are still hospitalized). the primary outcome is time to recovery by day 29 for patients with baseline ordinal score 4, 5 and 6. a key secondary outcome evaluates treatment-related improvements in the 8-point ordinal scale at day 15. each stage may prioritize different secondary endpoints for the purpose of multiple comparison analyses. contacts: 20-0006 central contact telephone: 1 (301) 7617948 email: dmidclinicaltrials@niaid.nih.gov

Eligibility criteria:
inclusion criteria: 1. admitted to a hospital with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adult \> / = 18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen or saliva, as documented by either of the following: * pcr or other assay positive in sample collected \< 72 hours prior to randomization; or * pcr or other assay positive in sample collected \>/= 72 hours but \< 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. 6. illness of any duration, and at least one of the following: * radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or * spo2 \< / = 94% on room air, or * requiring supplemental oxygen. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29. exclusion criteria: 1. anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. 2. subject meets criteria for ordinal scale category 6 or 7 at the time of screening. 3. subject has a positive test for influenza virus during this current hospital admission. 4. subjects with an estimated glomerular filtration rate (egfr) \< 30 ml/min are excluded unless in the opinion of the pi, the potential benefit of receiving remdesivir outweighs the potential risk of study participation. 5. alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 times the upper limits of normal. 6. total white cell blood cell count (wbc) \<1500 cells/microliter. 7. platelet count \<50,000/microliter. 8. history of chronic liver disease (e.g., jaundice, ascites, hepatic encephalopathy, history of bleeding esophageal or gastric varices). no laboratory testing is needed. 9. pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until three weeks after the last study product is given are not excluded). 10. allergy to any study medication including history of hypersensitivity to natural or recombinant interferon beta or human albumin. 11. patient has a chronic or acute medical condition or is taking a medication that cannot be discontinued at enrollment, that in the judgement of the pi, places them at unacceptable risk for a poor clinical outcome if they were to participate in the study. 12. received three or more doses of remdesivir, including the loading dose, outside of the study for covid-19. 13. received convalescent plasma or intravenous immunoglobulin \[ivig\] for the treatment of covid-19. 14. received any interferon product within two weeks of screening, either for the treatment of covid-19 or for a chronic medical condition (e.g., multiple sclerosis, hcv infection). 15. received any of the following in the two weeks prior to screening as treatment of covid-19: * small molecule tyrosine kinase inhibitors (e.g. baricitinib, imatinib, gefitinib, acalabrutinib, etc.); * monoclonal antibodies targeting cytokines (e.g., tnf inhibitors, anti-interleukin-1 \[il-1\], anti-il-6 \[tocilizumab or sarilumab\], etc.); * monoclonal antibodies targeting t-cells or b-cells as treatment for covid-19. 16. prior enrollment in actt-3.

Keywords: adaptive covid-19 efficacy multicenter novel coronavirus safety